Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sunitinib in High-Risk Stage III ccRCC
NCT06032728Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2023
- Primary completion
- Oct 2033
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Sunitinib with Observation (2 arms). Primary endpoint: Disease Free Survival at 10 years. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06032728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032728.